Mirae Asset Global Investments Co., Ltd. Zentalis Pharmaceuticals, Inc. Call Options Transaction History
Mirae Asset Global Investments Co., Ltd.
- $24 Billion
- Q4 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding ZNTL
# of Institutions
147Shares Held
65.3MCall Options Held
43.2KPut Options Held
21.7K-
Matrix Capital Management Company, LP Waltham, MA14MShares$34.6 Million2.05% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$11.9 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.48MShares$11.1 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$8.11 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.22MShares$7.98 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $141M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...